First Patient Imaged in SOFIE’s 18F-FAPI Phase 2 trial

Dulles, VA –May 12, 2023 – SOFIE Biosciences (SOFIE), an established US manufacturer and developer […]

2023-05-13T14:53:26+00:00May 12th, 2023|News|

Focus on FAPI Newsletter – Winter 2023

A WORD FROM OUR CHIEF SCIENTIFIC OFFICER

Dear FAPI community,

We would like to wish you […]

2023-02-08T02:13:11+00:00February 5th, 2023|Newsletter|

FAPI PET: Fibroblast Activation Protein Inhibitor Use in Oncologic and Nononcologic Disease

Yuriko Mori 1Katharina Dendl 1Jens […]

2023-02-05T19:37:28+00:00February 5th, 2023|Publications|

Novel 68Ga-FAPI PET/CT offers oncologic staging without COVID-19 vaccine-related pitfalls

Tristan T Demmert 1Ines Maric 1

2023-02-05T19:37:35+00:00February 5th, 2023|Publications|

SOFIE and Mayo Clinic collaborate to secure $3M NIH grant for FAPI clinical trial

The National Cancer Institute (NCI) has awarded Mayo Clinic (Rochester), in partnership with SOFIE, a […]

2023-02-01T12:50:06+00:00January 31st, 2023|News|

IND granted for FAP targeting therapeutic in SOFIE partnership

Dulles, VA – January 17, 2023 – SOFIE Biosciences (SOFIE), an established US manufacturer and developer […]

2023-01-31T20:45:42+00:00January 17th, 2023|News|

SOFIE granted IND for 18F-FAPI in Phase 2 study

Dulles, VA – November 29, 2022 – SOFIE Biosciences (SOFIE), an established US manufacturer and developer […]

2022-11-29T17:08:44+00:00November 29th, 2022|News|

Initial Results of FAPI-PET/MRI to Assess Response to Neoadjuvant Chemotherapy in Breast Cancer

Philipp Backhaus 1Matthias C Burg 2

2023-02-05T18:49:13+00:00November 17th, 2022|Publications|

3-time-point PET-analysis of FAPI-46 in a variety of cancers

Mahnoosh Naeimi 1Peter L Choyke 2

2023-02-05T18:45:28+00:00November 10th, 2022|Publications|

Focus on FAPI Newsletter – October 2022

A WORD FROM OUR CHIEF SCIENTIFIC OFFICER

We are excited to launch our FAPI newsletter […]

2023-02-05T19:31:50+00:00October 31st, 2022|Newsletter|
Go to Top